Compare LASR & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LASR | EWTX |
|---|---|---|
| Founded | 2000 | 2017 |
| Country | United States | United States |
| Employees | 800 | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.7B |
| IPO Year | 2018 | 2021 |
| Metric | LASR | EWTX |
|---|---|---|
| Price | $64.73 | $36.81 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $54.31 | $39.00 |
| AVG Volume (30 Days) | 990.9K | ★ 1.7M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.99 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $191,359,000.00 | N/A |
| Revenue This Year | $10.91 | N/A |
| Revenue Next Year | $14.32 | N/A |
| P/E Ratio | $6,488.00 | ★ N/A |
| Revenue Growth | ★ 38.09 | N/A |
| 52 Week Low | $16.87 | $12.31 |
| 52 Week High | $86.95 | $40.77 |
| Indicator | LASR | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.20 | 57.56 |
| Support Level | $63.48 | $28.73 |
| Resistance Level | $71.81 | $40.36 |
| Average True Range (ATR) | 5.43 | 2.61 |
| MACD | -0.84 | -0.01 |
| Stochastic Oscillator | 24.88 | 60.15 |
nLight Inc is a United States-based company provider of power semiconductor and fiber lasers for aerospace and defense, industrial, and microfabrication applications. It designs, manufactures, and sells a range of power semiconductor lasers and fiber lasers that are typically integrated into laser systems. It operates in two segments: Laser Products segment, which includes semiconductor lasers, fiber lasers, and directed energy products; and Advanced Development segment includes revenue earned from research and development contracts. The majority of its revenue is generated from the Laser segment. The company's geographical segments include North America, Asia Pacific, and EMEA, of which maximum revenue is derived from North America.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.